As neoadjuvant therapy in HER2+ early-stage breast cancer, ARX-788 alone or in combination with PD1 inhibitor is being evaluated in the I-SPY2 trial (NCT01042379).58 ARX788 has shown activity, including in some patients following T-DXd, and is being tested in combination with pyrotinib maleate as neoadjuvant treatment in a phase II or III clinical trials NCT05426486 and NCT04983121.60 This evidence concerns the gene ERBB2 and breast cancer.